What Comes Next Could Be a Once-in-a-Lifetime Opportunity

A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.

Click here now to watch the full briefing and discover the steps to take today.

Malcolm Fairbairn Biography and Net Worth

Director of TFF Pharmaceuticals

Mr. Fairbairn was the Co-Founder, President and Chief Investment Officer for Ascend Capital, a multi-billion dollar Long-Short Equity fund for almost 20 years. In particular, he led vertically specialized teams that invested across all market sectors. Prior to Ascend, Mr. Fairbairn established a successful track record as a Managing Director for Citadel, LLC, and as a portfolio manager for Strome Susskind LLC.
Mr. Fairbairn holds an MBA from Harvard Business School and an MS and BS from MIT in Chemical Engineering.

What is Malcolm Fairbairn's net worth?: The estimated net worth of Malcolm Fairbairn is at least $299.13 as of November 11th, 2020. Mr. Fairbairn owns 851 shares of TFF Pharmaceuticals stock worth more than $299 as of November 22nd. This net worth estimate does not reflect any other assets that Mr. Fairbairn may own. Learn More about Malcolm Fairbairn's net worth.
How do I contact Malcolm Fairbairn?: The corporate mailing address for Mr. Fairbairn and other TFF Pharmaceuticals executives is 2600 Via Fortuna Suite 360, Austin TX, 78746. TFF Pharmaceuticals can also be reached via phone at 817-438-6168 and via email at [email protected]. Learn More on Malcolm Fairbairn's contact information.
Has Malcolm Fairbairn been buying or selling shares of TFF Pharmaceuticals?: Malcolm Fairbairn has not been actively trading shares of TFF Pharmaceuticals in the last ninety days. Most recently, on Wednesday, May 19th, Malcolm Fairbairn bought 400 shares of TFF Pharmaceuticals stock. The stock was acquired at an average cost of $223.75 per share, with a total value of $89,500.00. Learn More on Malcolm Fairbairn's trading history.
Who are TFF Pharmaceuticals' active insiders?: TFF Pharmaceuticals' insider roster includes Kirk Coleman (CFO), Malcolm Fairbairn (Director), and Glenn Mattes (CEO). Learn More on TFF Pharmaceuticals' active insiders.

Malcolm Fairbairn Insider Trading History at TFF Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/19/2021	Buy	400	$223.75	$89,500.00
11/11/2020	Sell	2,533	$398.25	$1,008,767.25	851

Malcolm Fairbairn Buying and Selling Activity at TFF Pharmaceuticals

TFF Pharmaceuticals Company Overview

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Today's Range

Now: $0.35

$0.34

$0.54

50 Day Range

MA: $1.89

$0.35

$2.51

2 Week Range

Now: $0.35

$0.27

$11.00

Volume

14,440,301 shs

Average Volume

322,508 shs

Market Capitalization

$1.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32